Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a Phase 1 safety and pharmacokinetics study registration with no results posted; it describes planned enrollment and design only, typical of early-stage clinical development.
This is a Phase 3 RCT registration with no results posted; the study is actively recruiting and designed to test a novel PIK3CA inhibitor in advanced breast cancer, but outcome data are not yet available.
This is an active observational registry study with no reported results; it describes a planned real-world effectiveness evaluation in a specific population but carries no outcome data.
FDA supplemental approval for palbociclib (Ibrance) indicates a regulatory action granting efficacy-based authorization, but the record does not contain clinical trial data, endpoints, or comparative outcomes.